Survival improvement for patients with metastatic colorectal cancer over twenty years
Fadl A. Zeineddine(Methodist Hospital), John Paul Shen(The University of Texas MD Anderson Cancer Center), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Christine M. Parseghian(The University of Texas MD Anderson Cancer Center), Benny Johnson(The University of Texas MD Anderson Cancer Center), Van K. Morris(The University of Texas MD Anderson Cancer Center), Arvind Dasari(The University of Texas MD Anderson Cancer Center), Maria Pia Morelli(The University of Texas MD Anderson Cancer Center), Saikat Chowdhury(The University of Texas MD Anderson Cancer Center), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Mohammad A. Zeineddine(The University of Texas MD Anderson Cancer Center), Ryan Sun(The University of Texas MD Anderson Cancer Center), Bryan K. Kee(The University of Texas MD Anderson Cancer Center), Abdelrahman Yousef(University of New Mexico Hospital), Ryan Huey(The University of Texas MD Anderson Cancer Center), Jason Willis(The University of Texas MD Anderson Cancer Center), Jean‐Nicolas Vauthey(The University of Texas MD Anderson Cancer Center), Yoshikuni Kawaguchi(The University of Texas MD Anderson Cancer Center), Yue Gu(The University of Texas MD Anderson Cancer Center), Michael S. Lee(Duke Medical Center), Michael J. Overman(The University of Texas MD Anderson Cancer Center)
Cited by 172
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS)
|Surgery|2011|2.3k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k